A study result shows implantable type continuous glucose monitoring (CGM) systems are accurate and safe to use compared to transcutaneous type continuous glucose monitoring (CGM) systems. Implantable type continuous glucose monitoring (CGM) systems require minor surgical procedure but usage benefits with them are
Researchers evaluated the performance of the Eversense (Senseonics Inc) implantable CGM systems in 71 individuals with type 1 (T1D) and type 2 diabetes (T2D). Results show improvements in HbA1c levels. The study findings were published in Diabetes Care.
Researchers say body bone loss is associated with diabetes and osteoporosis is the consequence of diabetes. Both diabetes and osteoporosis conditions increases as individual ages. Diabetes effects are as follows
Tips to prevent osteoporosis and diabetes are
Sensogram Technologies is a global leader in wireless and wearable devices. The company successfully completed three pilot clinical studies of the SensoSCAN wearable device. Sensogram President Ernie Ianace says the company is planning to conduct further studies by including testing the product with blood oxygen saturation, heartbeat rate and respiration rate parameters. Features of SensoSCAN product are
The device reads blood pressure of an individual in real-time with optical scanning technology and sends real-time data to the cloud (wireless communication). Needed individuals can access the real-time data through mobile App. The company says this technology can be used in wearable devices to be used in clinical care, sports, PERS (Public Employees Retirement System), military etc. The company already started implementing the new technology and product. The product will be available in health and wellness applications in the United States market during January 2017.
According to media reports, Chinese consumer electronics company Meizu introduced the Fitbit-like device at a fraction of cost. A touchscreen display of the Meizus H1 product contains a hidden OLED screen. The OLED screen of the product displays
Features of the Meizus H1 product are
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.